23 Feb Senti Biosciences
Tim Lu, M.D, Ph.D., CEO and Co-Founder
Oct. 11 | 3:15pm | Ecolab Life Sciences Ballroom
South San Francisco, CA
(NASDAQ: SNTI)
Senti’s mission is to create a new generation of smarter medicines that outmaneuver incurable diseases using the Gene Circuit technology. We utilize off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells, outfitted with Gene Circuit technologies, to target particularly challenging liquid and solid tumor oncology indications. Our lead product candidate is SENTI-202 for the treatment of CD33 and/or FLT3 expressing hematologic malignancies with a focus on acute myeloid leukemia (AML). Additionally, our SENTI-401 program is being designed for the treatment of colorectal cancer (CRC) and other CEA-positive cancers. We have also demonstrated in preclinical studies the potential breadth of our Gene Circuits in other modalities, including T cells, adeno-associated viruses (AAVs) and induced pluripotent stem cells (iPSCs), and diseases outside of oncology; and we have executed partnerships with Spark Therapeutics and BlueRock Therapeutics to advance these capabilities.
